Clinical Trials
63 trialsNCT02867592 2026-05-27
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03866382 2026-05-26
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07293351 2026-05-26
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT07405164 2026-05-26
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT05263050 2026-05-22
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Phase 2 Recruiting
NCT02496208 2026-05-13
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03793166 2026-05-13
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04071223 2026-05-13
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05411081 2026-05-13
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07227402 2026-05-12
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04022343 2026-05-05
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Emory University
Phase 2 Active not recruiting
NCT04586231 2026-05-05
MK-6482-011
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05663710 2026-05-05
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05327686 2026-05-04
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT06835972 2026-05-04
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT05536141 2026-05-01
ARC-20
Arcus Biosciences, Inc.
Phase 1 Recruiting
NCT05361720 2026-04-27
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT06026410 2026-04-14
FIT-001
Kura Oncology, Inc.
Phase 1 Recruiting
NCT05048212 2026-04-09
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03798626 2026-04-01
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
NCT04514484 2026-03-23
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04338269 2026-03-19
CONTACT-03
Hoffmann-La Roche
Phase 3 Terminated
NCT03945773 2026-03-13
CaboPoint
Ipsen
Phase 2 Completed
NCT05012371 2026-03-05
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05122546 2026-03-05
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT06716853 2026-02-09
TEM-GU
Genenta Science
Phase 1/2 Terminated
NCT07383441 2026-02-03
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
SWOG Cancer Research Network
Phase 3 Not yet recruiting
NCT07077161 2026-01-28
SKIPPY 2
Leiden University Medical Center
Phase 2 Recruiting
NCT04413123 2026-01-21
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05092373 2026-01-14
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03541902 2026-01-09
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06132945 2025-11-14
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05931393 2025-10-10
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT07028125 2025-10-07
CANIQOL
Centre Francois Baclesse
Phase 4 Recruiting
NCT06934057 2025-09-24
CABOLD
Gustave Roussy, Cancer Campus, Grand Paris
Phase 4 Recruiting
NCT07187869 2025-09-23
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT03635892 2025-09-22
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03937219 2025-09-10
COSMIC-313
Exelixis
Phase 3 Active not recruiting
NCT03170960 2025-08-17
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
Phase 1 Active not recruiting
NCT03685448 2025-08-08
UNICAB
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Completed
NCT03967522 2025-08-08
CABRAMET
Centre Leon Berard
Phase 2 Completed
NCT03141177 2025-06-06
CheckMate 9ER
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05127824 2025-05-04
Autologous Dendritic Cell Vaccine in Kidney Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT04322955 2025-04-25
Cyto-KIK
Columbia University
Phase 2 Recruiting
NCT03149822 2025-03-13
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
University of Colorado, Denver
Phase 1/2 Completed
NCT06364631 2025-01-16
CARE1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT02761057 2025-01-13
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
Phase 2 Completed
NCT03634540 2024-12-20
MK-6482-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Active not recruiting
NCT05188118 2024-11-06
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Recruiting
NCT03200587 2024-07-03
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
University of Utah
Phase 1 Completed